Showing results (11-20 of 65) with videos related to
Sort By:
Pageof 7
NPJ Precision Oncology|April 16, 2024
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscapeDavid Planchard, Rachel E Sanborn, Marcelo V Negrao, et al.Biorxiv : the Preprint Server for Biology|February 12, 2026
Activity Profiling of Mycobacterial L,D-TranspeptidasesKarl L Ocius, Rachel E Sanborn, Ananya Naick, et al.Biochemistry|May 22, 2026
Peptide Mimetic Platform for Activity Profiling of Mycobacterial l,d-TranspeptidasesKarl L Ocius, Rachel E Sanborn, Ananya Naick, et al.Frontiers in Oncology|January 26, 2024
Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatmentsMo Yang, Erin Mandal, Frank X Liu, et al.Journal of Medical Economics|December 20, 2021
Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providersRobert S Epstein, Roshanthi K Weerasinghe, Amy S Parrish, et al.Annals of Family Medicine|May 13, 2020
Results of Lung Cancer Screening in the CommunityJohn R Handy, Michael Skokan, Erika Rauch, et al.Cancer|September 2, 2016
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113Rachel E Sanborn, Jyoti D Patel, Gregory A Masters, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2023
Cancer's Dark Matter: Lighting the Abyss Unveils Universe of New TherapiesBernard A Fox, Walter J Urba, Shawn M Jensen, et al.Clinical Lung Cancer|April 24, 2018
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic InflammationGiuseppe Giaccone, Rachel E Sanborn, Saiama N Waqar, et al.Investigational New Drugs|February 17, 2017
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553)Susanne M Arnold, Kari Chansky, Markos Leggas, et al.Pageof 7